Literature DB >> 8734284

[Hypercalcitoninemia in conditions other than medullary cancers of the thyroid].

P Niccoli1, B Conte-Devolx, P J Lejeune, P Carayon, J F Henry, F Roux, N Wion-Barbot, J C Bigorgne.   

Abstract

Serum calcitonin (CT) assays are the most useful tumoral marker for the diagnosis and follow up of medullary thyroid carcinoma (MTC). Since 1988 the sensitivity and specificity of CT assays have been considerably improved. Normal basal and pentagastrin (Pg) stimulated CT ranges remain to be established and it appears necessary to determine the pathological circumstances which may be responsible for hypercalcitoninemia in addition to MCT. By reviewing literature and data from the "Groupe d'Etude des Tumeurs à Calcitonine": a/we compared basal and Pg stimulated CT values obtained with two commercially available immunometric CT assays and we observed that CT values measured by the CT-EASIA MEDGE-NIX kit were three fold the values obtained by suing the hGH ELSA CIS BIOINDUSTRIE Kit; b/we determined that hypercalcitoninemia may be observed in isolated C Cell Hyperplasia (HCC) surrounding either lymphocytic thyroiditis or follicular thyroid carcinoma loci, in chronic renal failure on maintenance hemodialysis, and in various neuroendocrine tumors. Surprisingly, the hypercalcitoninemia related to HCC has been found in genetically unaffected members (without any identified gene RET mutation) of both a Multiple Endocrine Neoplasia type 2A and isolated familial hereditary MTC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734284

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  7 in total

1.  Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.

Authors:  Alicia Algeciras-Schimnich; Carol M Preissner; J Paul Theobald; Mary S Finseth; Stefan K G Grebe
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

2.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone.

Authors:  F Massaro; M Dolcino; R Degrandi; D Ferone; M Mussap; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

4.  Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Luca Giovanella
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

Review 5.  Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility.

Authors:  Shui Boon Soh; Tar Choon Aw
Journal:  Ann Lab Med       Date:  2019-01       Impact factor: 3.464

6.  Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults.

Authors:  Eyun Song; Min Ji Jeon; Hye Jin Yoo; Sung Jin Bae; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Hong-Kyu Kim; Won Gu Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-07

7.  Sporadic medullary thyroid carcinoma: clinical data from a university hospital.

Authors:  Joya Emilie M Correia-Deur; Rodrigo A Toledo; Alice T Imazawa; Delmar M Lourenço; Marilza C L Ezabella; Marcos R Tavares; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.